QAT 370
Alternative Names: QAT370Latest Information Update: 03 Dec 2009
At a glance
- Originator Novartis
- Class Antiasthmatics
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 08 Feb 2006 Phase-I clinical trials in Chronic obstructive pulmonary disease (Inhalation)